$Sarepta Therap(SRPT.US) | Mizuho reiterates ๐๐ฎ๐ญ๐ฉ๐๐ซ๐๐จ๐ซ๐ฆ on ๐๐๐ซ๐๐ฉ๐ญ๐, maintains ๐๐ ๐๐ญ $๐๐ following ๐ฉ๐จ๐ฌ๐ข๐ญ๐ข๐ฏ๐ ๐ ๐๐ ๐ง๐๐ฐ๐ฌ
Analyst sees FDA's sNDA acceptance for two DMD drugs as a positive, de-risking event given past trial data concerns.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments